| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/03/2005 | US20050027007 Allylamides useful in the treatment of alzheimer's disease |
| 02/03/2005 | US20050026990 N-[(3S)-1-hydroxy-2-oxopyrrolidinyl]-N-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonamide or derivatives to treat Respiratory system disorders; arthritis, and bone disorders |
| 02/03/2005 | US20050026986 Use of central cannabinoid receptor antagonists for the preparation of drugs |
| 02/03/2005 | US20050026983 Imidazole compounds and uses thereof |
| 02/03/2005 | US20050026981 Stable oral solid drug composition |
| 02/03/2005 | US20050026980 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases |
| 02/03/2005 | US20050026973 New heterocyclic oxime compounds |
| 02/03/2005 | US20050026967 Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases |
| 02/03/2005 | US20050026963 Pyrazole substituted directly, or by a bridge, with a heteroaryl group containing N adjacent to the point of connection of the heteroaryl useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, bipolar disorder, circadian rhythm and sleep disorders |
| 02/03/2005 | US20050026956 Carbinols for the treatment of neuropathic dysfunction |
| 02/03/2005 | US20050026946 GSK-3 inhibitors |
| 02/03/2005 | US20050026938 Purine inhibitors of protein kinases, G proteins and polymerases |
| 02/03/2005 | US20050026932 Adenosine A2a receptor antagonists |
| 02/03/2005 | US20050026927 Pyrazole derivatives as psychopharmaceuticals |
| 02/03/2005 | US20050026926 N, N'-disubstituted piperazine compounds and their use as analgesics |
| 02/03/2005 | US20050026922 For treating CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression; side effect reduction; for example, (7R,9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine |
| 02/03/2005 | US20050026915 As melanin concentrating hormone (MCH)receptor antagonists, for prevention or treatment of obesity or eating disorders; (2E)-3-(4-chlorophenyl)-N-[2-(dimethylamino)quinolin-6-yl]prop-2-enamide |
| 02/03/2005 | US20050026913 N-substituted aniline and diphenylamine analogs; exhibit improved PDE4 inhibition; novel rolipram analogs which facilitate entry into cells, especially cells of the nervous system |
| 02/03/2005 | US20050026908 Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer |
| 02/03/2005 | US20050026906 Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide; for control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain |
| 02/03/2005 | US20050026904 Cathepsin S, K, F, L and B reversible inhibitory amidino and guanidino peptidyl compounds useful for treating autoimmune diseases, rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis |
| 02/03/2005 | US20050026900 Metabolite |
| 02/03/2005 | US20050026899 11-Piperazin-1-yldibenzo[b,f][1,4]thiazepine or its pharmaceutically acceptable salts; for treating anxiety, agitation, hostility, panic, eating disorders, affective symptoms, mood symptoms, negative and positive psychotic symptoms commonly associated with schizophrenia, dementia, anxiety, depression |
| 02/03/2005 | US20050026895 Having a superior acetylcholinesterase inhibitory action; treatment of Alzheimer's disease, brain disorders, attention deficit disorders; side effect reduction |
| 02/03/2005 | US20050026875 Treating bacterial, viral, or fungal infections, cancer, a lung injury, an eye disorder, neurological disorder or stroke |
| 02/03/2005 | US20050026840 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics |
| 02/03/2005 | US20050026822 Human 3 relaxin |
| 02/03/2005 | US20050026811 antagonists for the receptor for advanced glycated endproducts(RAGE), used for treatment of Alzheimer's disease |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050025841 Therapeutic methods using herbal compositions |
| 02/03/2005 | US20050025806 A silicone support of methylvinylsiloxane polymer including a fumed silca reinforcement filler; growth and/or reproduction-associated drug, derivative or analogue and carrier; each implant of insufficient size and/or payload for the predetermined threshold blood level of indicated drug; high-speed |
| 02/03/2005 | US20050025767 Contains antibody binding to macrophage migration inhibitory factor |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | DE202004013132U1 Chewable tablets with calming, anxiolytic and hypnotic actions, for medicinal, dietary or veterinary use, containing synergistic combination of herbal preparation and aromatherapeutic components |
| 02/03/2005 | DE202004009689U1 Combating stress states or nervous system or metabolic disorders, using glycine as neurotransmission modulator showing antistress, stress protective, nootropic and toxin binding actions |
| 02/03/2005 | DE10360086A1 Ambroxolhaltige Tabletten Ambroxol tablets |
| 02/03/2005 | DE10332473A1 Ambroxol für die Behandlung von Epilepsie Ambroxol for the treatment of epilepsy |
| 02/03/2005 | DE10130504B4 Xanthin- und Phenazon-Acesulfam-H-Komplexe mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung Xanthine-phenazone and acesulfame-H-complexes with improved taste, process for their preparation and their use |
| 02/03/2005 | CA2770493A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2533136A1 Perinatal hypoxic-ischemic brain damage treatment |
| 02/03/2005 | CA2533117A1 Combinations for the treatment of depression |
| 02/03/2005 | CA2532071A1 Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| 02/03/2005 | CA2531490A1 Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
| 02/03/2005 | CA2529036A1 Indane derivates as muscarinic receptor agonists |
| 02/03/2005 | CA2528586A1 Cyclohexanecarboxylic acid compound |
| 02/02/2005 | EP1502600A1 Use of botulinum toxin for treating smooth muscle disorders |
| 02/02/2005 | EP1502597A1 Compositions for the treatment of anxiety and associated disorders |
| 02/02/2005 | EP1502593A1 The use of Stanozolol for the preparation of anti-inflammatory and anti-degenerative drugs |
| 02/02/2005 | EP1502592A1 Controlled release oxycodone compositions |
| 02/02/2005 | EP1502591A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1501946A2 Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501923A2 Pak5-related compositions and methods |
| 02/02/2005 | EP1501866A2 Apo-2 ligand variants and uses thereof |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501828A1 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501826A2 Substituted indoles as alpha-1 agonists |
| 02/02/2005 | EP1501823A1 New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501817A1 Imidazolinylmethyl aralkylsulfonamides |
| 02/02/2005 | EP1501814A1 Semicarbazide derivatives for combating thromboembolic diseases |
| 02/02/2005 | EP1501809A1 Triazole derivatives as tachykinin receptor antagonists |
| 02/02/2005 | EP1501808A1 Tachykinin receptor antagonists |
| 02/02/2005 | EP1501807A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists |
| 02/02/2005 | EP1501804A1 Isoquinoline derivatives mao-b inhibitors |
| 02/02/2005 | EP1501801A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 02/02/2005 | EP1501800A1 Bombesin antagonists |
| 02/02/2005 | EP1501794A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| 02/02/2005 | EP1501787A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501539A1 Method for control of depression using c terminal growth hormone (gh) fragment |
| 02/02/2005 | EP1501533A2 Peptide inhibitors of protein kinase c ϝ for pain management |
| 02/02/2005 | EP1501532A2 Peptide inhibitors of protein kinase c |
| 02/02/2005 | EP1501531A1 Method for treating anxiety and mood disorders in older subjects |
| 02/02/2005 | EP1501525A1 Method for producing preparations rich in tocotrienol |
| 02/02/2005 | EP1501523A1 Carbon monoxide as a biomarker and therapeutic agent |
| 02/02/2005 | EP1501518A2 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501513A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 02/02/2005 | EP1501512A2 4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1501511A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| 02/02/2005 | EP1501510A1 The treatment of pain with ifenprodil |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501505A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -t riazole for the treatment of autoimmune diseases |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501503A1 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatment of central nervous system disturbances |
| 02/02/2005 | EP1501499A1 Trans-epicutaneous administration form for treating restless leg syndrome |
| 02/02/2005 | EP1501497A2 Catechin multimers as therapeutic drug delivery agents |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501467A2 Heterocyclo inhibitors of potassium channel function |
| 02/02/2005 | EP1390365B1 Novel sulfonate substituted pyrazol pyridine dervivatives |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1351980A4 Peptides for activation and inhibition of delta pkc |
| 02/02/2005 | EP1330233B1 Method of treating stroke |